Paratek Pharmaceuticals Inc (NASDAQ:PRTK) was the target of a significant increase in short interest in August. As of August 31st, there was short interest totalling 10,975,100 shares, an increase of 7.4% from the July 31st total of 10,218,500 shares. Based on an average trading volume of 342,800 shares, the short-interest ratio is presently 32.0 days. Currently, 41.0% of the shares of the company are sold short.
A number of hedge funds have recently added to or reduced their stakes in PRTK. Bank of Montreal Can boosted its holdings in Paratek Pharmaceuticals by 503.1% during the second quarter. Bank of Montreal Can now owns 7,816 shares of the specialty pharmaceutical company’s stock worth $31,000 after buying an additional 6,520 shares in the last quarter. BNP Paribas Arbitrage SA purchased a new stake in Paratek Pharmaceuticals during the first quarter worth about $36,000. Alambic Investment Management L.P. purchased a new stake in Paratek Pharmaceuticals during the second quarter worth about $82,000. Bank of America Corp DE boosted its holdings in Paratek Pharmaceuticals by 43.1% during the fourth quarter. Bank of America Corp DE now owns 23,504 shares of the specialty pharmaceutical company’s stock worth $120,000 after buying an additional 7,074 shares in the last quarter. Finally, A.R.T. Advisors LLC purchased a new stake in Paratek Pharmaceuticals during the second quarter worth about $121,000. 71.34% of the stock is currently owned by hedge funds and other institutional investors.
Several analysts have recently weighed in on the stock. HC Wainwright set a $27.00 target price on shares of Paratek Pharmaceuticals and gave the company a “buy” rating in a report on Monday, September 9th. ValuEngine raised shares of Paratek Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Finally, Zacks Investment Research raised shares of Paratek Pharmaceuticals from a “sell” rating to a “hold” rating and set a $4.75 target price on the stock in a report on Friday, August 9th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $18.79.
Paratek Pharmaceuticals (NASDAQ:PRTK) last released its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported ($1.02) EPS for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.14. The firm had revenue of $2.05 million for the quarter, compared to the consensus estimate of $1.86 million. Paratek Pharmaceuticals had a negative net margin of 597.22% and a negative return on equity of 459.96%. As a group, equities research analysts predict that Paratek Pharmaceuticals will post -4.31 earnings per share for the current year.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.
See Also: What is a balanced fund?
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.